We are experiencing 4 week turn-around time in review of submissions and resubmissions. We recommend commencing this process concurrently with your ethics submission and allowing at least 8 weeks for registration to be completed from date of first submission. We currently do not have the capacity to expedite reviews.

Note also there are delays to review of updates. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03038113




Registration number
NCT03038113
Ethics application status
Date submitted
30/01/2017
Date registered
31/01/2017
Date last updated
24/12/2020

Titles & IDs
Public title
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B
Scientific title
A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Secondary ID [1] 0 0
BP39405
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - RO7062931
Treatment: Drugs - Placebo
Treatment: Drugs - Immune Modulator

Experimental: Part 1: Single-Ascending Dose (SAD) - Healthy volunteers will be enrolled in up to 8 cohorts with doses starting from 0.1 mg/kg and escalating sequentially after review of safety and pharmacokinetic (PK) data.

Experimental: Part 2: Multiple Ascending Dose - Participants with Chronic Hepatitis B will enrolled in Part 2. In Part 2a, participants will receive two monthly injections of either 3 doses equivalent to a multiple of the saturation dose or placebo in a 1:1:1:1 ratio. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts where they will be dosed weekly (QW) or bi-weekly (Q2W). Each of the cohorts in Part 2b will include participants receiving active drug or placebo in a 3:1 ratio. In Part 2c, NUC-suppressed CHB participants will receive either RO7062931+NUC for up to 24 weeks, or RO7062931+NUC+an immune modulator for up to 48 weeks, at a dose determined from Part 2a and 2b. Part 2c may also enroll treatment-naive immune-active CHB participants.


Treatment: Drugs: RO7062931
Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b, a dose selected from Part 2a will be administered to participants randomized into 4 cohorts QW or Q2W. In Part 2c, participants will receive RO7062831 QW on top of another therapy for up to 24 or 48 weeks.

Treatment: Drugs: Placebo
Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.

Treatment: Drugs: Immune Modulator
Participants in Part 2c will receive an immune modulator subcutaneously QW for up to 48 weeks.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest - An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
AEs of Special Interest were defined as: i.) elevated ALT/AST in combination with elevated bilirubin/clinical jaundice, ii.) suspected transmission of infectious agent by the study drug, iii.) severe injection site reactions, iv.) ALT elevation =10x ULN, v.) creatinine elevation =1.5x ULN or =50% from baseline.
Timepoint [1] 0 0
Up to day 113
Primary outcome [2] 0 0
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 1 - Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.
Timepoint [2] 0 0
Screening, Days -1, 2, 8, 15, 29, 85
Primary outcome [3] 0 0
Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results - Part 2 - Marked reference range has been predefined for each laboratory parameter. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range that also represent a defined change from baseline will be considered marked laboratory abnormalities (i.e., potentially clinically relevant). If a baseline value is not available for a study subject, the midpoint of the standard reference range will be used as the study participant baseline value for the purposes of determining marked laboratory abnormalities.
Timepoint [3] 0 0
Screening, Days -1, 2, 8, 15, 29, at discontinuation, Days 36, 43, 57, 85, 113
Primary outcome [4] 0 0
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 1 - Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF > 500 msec, or > 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.
Timepoint [4] 0 0
Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
Primary outcome [5] 0 0
Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation - Part 2 - Participants were monitored for clinically-significant RO7062931-related ECG changes, defined as QTcF > 500 msec, or > 60 msec longer than the pre-dose baseline, within the first 48 hours post-dose.
Timepoint [5] 0 0
Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
Primary outcome [6] 0 0
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 1 - Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
Timepoint [6] 0 0
Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
Primary outcome [7] 0 0
Percentage of Participants With U-Wave Abnormalities Based on U-Wave Assessment - Part 1 - Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
Timepoint [7] 0 0
Day 1 (1,4,8,12h), Days 2 and 8, Follow Up Days 15, 29, 85
Primary outcome [8] 0 0
Percentage of Participants With T-Wave Abnormalities Based on T-Wave Assessment - Part 2 - Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
Timepoint [8] 0 0
Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
Primary outcome [9] 0 0
Percentage of Participants With U-Wave Based on U-Wave Assessment - Part 2 - Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
Timepoint [9] 0 0
Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
Primary outcome [10] 0 0
Percentage of Participants With QTcF Values Between 450 Msec - 480 Msec - Part 2 - Table entries provide the percentage of participants with abnormalities during treatment assessment. Abnormalities reported in participants with missing baseline values are included. Baseline is the Participant's last observation prior to initiation of study drug.
Timepoint [10] 0 0
Day 1 (1,4,8h), Days 2,8,15,22 (1h and 8h), Day 23, Day 29 (1,4,8h), Day 30, Follow Up Days 36, 43, 50, 57, 78, 85, 106, 113
Secondary outcome [1] 0 0
Maximum Plasma Concentration (Cmax) After Single Ascending Doses - Part 1 - Cmax values are the the peak plasma concentration reached after administration of RO7062931.
Timepoint [1] 0 0
Days 1-8
Secondary outcome [2] 0 0
Cmax After Multiple Ascending Doses - Part 2 - Cmax values are the the peak plasma concentration reached after administration of RO7062931.
Timepoint [2] 0 0
Days 1-113
Secondary outcome [3] 0 0
Time to Reach Maximum Plasma Concentration (Tmax) After Single-Ascending Doses - Part 1 - Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.
Timepoint [3] 0 0
Days 1-8
Secondary outcome [4] 0 0
Tmax After Multiple Ascending Doses - Part 2 - Tmax values are the amount of time to maximum concentration in plasma after administration of RO7062931.
Timepoint [4] 0 0
Days 1-113
Secondary outcome [5] 0 0
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) After Single-Ascending Doses - Part 1 - AUC0-inf was calculated based on non-compartmental analysis.
Timepoint [5] 0 0
Days 1-8
Secondary outcome [6] 0 0
AUC0-inf After Multiple Ascending Doses - Part 2 - AUC0-inf was calculated based on non-compartmental analysis.
Timepoint [6] 0 0
Days 1,22,29
Secondary outcome [7] 0 0
Area Under the Plasma Concentration-Time Curve From Time Zero Until the Last Quantifiable Time-Point (AUC0-last) After Single Ascending Doses - Part 1 - AUC0-last was calculated based on non-compartmental analysis.
Timepoint [7] 0 0
Days 1-8
Secondary outcome [8] 0 0
AUC0-last After Multiple Ascending Doses - Part 2 - AUC0-last was calculated based on non-compartmental analysis.
Timepoint [8] 0 0
Days 1,22,29
Secondary outcome [9] 0 0
Terminal Elimination Half-Life (t1/2) After Single Ascending Doses - Part 1 - T1/2 was calculated based on non-compartmental analysis.
Timepoint [9] 0 0
Days 1-8
Secondary outcome [10] 0 0
Terminal Elimination Half-Life (t1/2) After Multiple Ascending Doses - Part 2 - T1/2 was calculated based on non-compartmental analysis.
Timepoint [10] 0 0
Days 1-113
Secondary outcome [11] 0 0
Total Clearance (CL) After Single Ascending Doses - Part 1 - Apparent oral clearance was calculated from Dose/AUCinf.
Timepoint [11] 0 0
Days 1-8
Secondary outcome [12] 0 0
Total Clearance (CL) After Multiple Ascending Doses - Part 2 - Apparent oral clearance was calculated from Dose/AUCinf.
Timepoint [12] 0 0
Days 1-113
Secondary outcome [13] 0 0
Volume of Distribution (Vss) After Single Ascending Doses - Part 1 - Vss was calculated from dose/AUCinf
Timepoint [13] 0 0
Days 1-8
Secondary outcome [14] 0 0
Volume of Distribution (Vss) After Multiple Ascending Doses - Part 2 - Vss was calculated from dose/AUCinf
Timepoint [14] 0 0
Days 1-113
Secondary outcome [15] 0 0
Cumulative Amount Excreted Unchanged in Urine (Ae) After Single Ascending Doses - Part 1 - Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.
Timepoint [15] 0 0
Hours 0-4, 0-8, 0-12, and 0-24
Secondary outcome [16] 0 0
Cumulative Amount Excreted Unchanged in Urine (Ae) After Multiple Ascending Doses - Part 2 - Ae: cumulative amount of drug excreted in urine over a 24 hour period or over defined time periods linked to the pools of urine collected.
Timepoint [16] 0 0
Days 1-113
Secondary outcome [17] 0 0
Change From Baseline of Quantitative HBsAg (qHBsAg) (log10) After Multiple Ascending Doses - Part 2 - HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
Timepoint [17] 0 0
Days 1-113
Secondary outcome [18] 0 0
Summary of Maximum qHBsAg Decrease on Days 1-113 - Part 2 - HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
Timepoint [18] 0 0
Day 1 - Day 113
Secondary outcome [19] 0 0
Summary of Time to Maximum qHBsAg Decrease on Day 1-113 - Part 2 - HBsAg is a viral parameter that can be affected by the action of RO7062931. A change from baseline in qHBsAg can indicate the drug's effect.
Timepoint [19] 0 0
Day 1 - Day 113

Eligibility
Key inclusion criteria
FOR HEALTHY VOLUNTEERS ONLY - PART 1 -

- A Body Mass Index (BMI) between 18 to 30 kg/m2 inclusive and a body weight of at least
50 kg.

- Women should be of non-childbearing potential. A woman is considered to be of
childbearing potential if she is post-menarcheal but has not reached a post-menopausal
state and has not undergone surgical sterilization (removal of ovaries and/or uterus).

- Men must agree to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures during treatment and up to 105 days after the last dose, and
agree to refrain from donating sperm.

- Non-smoker (nor tobacco containing products) for at least 90 days prior to dosing on
Day 1 and agree to remain as non-smoker during the study.

FOR CHB PARTICIPANTS ONLY - PARTS 2a and 2b:

- A BMI between 18 to 32 kg/m2 inclusive.

- Chronic hepatitis B (HBV) infection.

- Positive test for HBsAg for more than 6 months prior to randomization and HBsAg titer
= 10^3 IU/mL at screening.

- On entecavir, tenofovir, adefovir or telbivudine treatment for at least 6 months prior
to randomization and will remain on stable treatment during the study.

- HBV deoxyribonucleic acid (DNA) = 90 IU/mL for at least the preceding 6 months.

- Screening laboratory values (hematology, chemistry, urinalysis) obtained up to 56 days
prior to first study treatment within normal ranges.

- Liver biopsy, fibroscan® or equivalent test obtained within the past 6 months
demonstrating liver disease consistent with chronic HBV infection without evidence of
bridging fibrosis or cirrhosis

- Women should be of non-childbearing potential. A woman is considered to be of
childbearing potential if she is post-menarcheal but has not reached a post-menopausal
state and has not undergone surgical sterilization (removal of ovaries and/or uterus).

- Men must agree to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures during treatment and up to 105 days after the last dose, and
agree to refrain from donating sperm.

FOR CHB PARTICIPANTS ONLY - PART 2c

- BMI between 18 to 32 kg/m2 inclusive

- CHB infection (HBsAg-positive for at least 6 months)

- For NUC-suppressed CHB participants: Must have been treated with a single NUC for at
least 12 months, and have been on the same NUC therapy for at least 3 months prior to
screening; HBV DNA <lower limit of quantification (LLOQ) at screening and in the 6
months prior to screening (at least one measurement must be >30 days prior to
screening); alanine aminotransferase (ALT) </=2x upper limit of normal (ULN) for >6
months prior to screening and confirmed at screening; total bilirubin within normal
range at screening, except for patients with Gilbert's syndrome

- For treatment-naive and immune-active participants: HBV DNA at screening >/=2x10^4
IU/mL for HBeAg positive participants, or >/=2x10^3 IU/mL for HBeAg negative
participants; elevated serum ALT>2 ULN to </=5, 2 values within 6 months, at least one
of which is at screening and that are at least 14 days apart; total bilirubin within
normal range except for participants with Gilbert's syndrome

- Screening laboratory values (hematology, chemistry, urinalysis) obtained up to 28 days
prior to first study treatment within normal ranges

- Liver biopsy, fibroscan, or equivalent test obtained within the last 6 months
demonstrating liver disease consistent with chronic HBV infection without evidence of
bridging fibrosis or cirrhosis

- Women should be of non-childbearing potential

- Men must agree to remain abstinent or use contraception, and agree to refrain from
donating sperm
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
FOR HEALTHY VOLUNTEERS ONLY - PART 1:

- History of drug or alcohol abuse or dependence in previous 6 months.

- Positive urine drug and alcohol screen or positive cotinine test at screening or Day
-1.

- Positive result on hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency
virus (HIV) 1 and 2.

- Confirmed blood pressure or resting pulse rate outside of accepted ranges.

- Participation in an investigational drug or device study within 90 days prior to
screening.

- Donation of blood over 500 mL within three months prior to screening.

- Any major illness within the one month, or any febrile illness within two weeks
preceding the screening visit.

- Alcohol consumption of more than 2 standard drinks per day on average.

FOR CHB PARTICIPANTS ONLY - PARTS 2a and 2b:

- History or other evidence of bleeding from esophageal varices.

- Decompensated liver disease.

- History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) = 13
ng/mL at Screening

- History or other evidence of a medical condition associated with chronic liver disease
other than HBV infection.

- Documented history or other evidence of metabolic liver disease within one year of
randomization or documented history of infection with hepatitis D virus.

- Positive test for hepatitis A (IgM anti-HAV), hepatitis C, or HIV.

- Organ transplantation.

- Significant acute infection or any other clinically significant illness within 2 weeks
of randomization.

- Abnormal renal function.

- Participation in an investigational drug or device study within 30 days prior to
randomization.

- Donation or loss of blood over 500 mL within 3 months prior to starting study
medication.

- Administration of any blood product within 3 months of randomization.

- History or evidence of alcohol abuse (consumption of more than 2 standard drinks per
day on average).

FOR CHB PARTICIPANTS ONLY - PART 2c

- History or other evidence of bleeding from esophageal varices

- Evidence of liver cirrhosis or decompensated liver disease

- One or more of the following laboratory abnormalities at screening: Total serum
bilirubin > ULN (except for participants with Gilbert's disease); international
normalized ratio (INR) > 1.1 ULN; serum albumin < 3.5 g/dL; AFP >13 ng/mL; positive
results for anti-mitochondrial antibodies (AMA > 1:80), anti-nuclear antibody (ANA >
1:80), anti-smooth muscle antibody (ASMA > 1:40), anti-thyroperoxidase antibodies
(a-TPO), anti-thyroglobulin, or anti-platelet antibodies; thyroid stimulating hormone
(TSH) outside of normal range; platelet count <100,000 cells/mm^3; hemoglobin <12 g/dL
(females) or <13 g/dL (males); white blood cell count <2500 cells/mm^3; and neutrophil
count <1500 cells/mm^3

- History or other evidence of a medical condition associated with chronic liver disease
other than HBV infection

- History of thyroid disease poorly controlled on prescribed medications or clinically
relevant abnormal thyroid function tests

- Documented history or other evidence of metabolic liver disease within one year of
randomization

- Positive test for hepatitis A, hepatitis C, or HIV

- History of organ transplantation

- Participation in an investigational drug or device study within 30 days prior to
screening or previous treatment with an investigational agent for HBV within 6 months
prior to screening

- Significant acute infection or any other clinically significant illness within 2 weeks
of randomization

- Abnormal renal function, including serum creatinine > ULN or calculated creatinine
clearance < 70 mL/min

- Donation or loss of blood over 500 mL within 3 months prior to randomization

- Administration of any blood product within 3 months prior to randomization

- History of alcohol abuse and/or drug abuse

Study design
Purpose of the study
Basic Science
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [2] 0 0
Linear Clinical Research Limited - Nedlands
Recruitment postcode(s) [1] 0 0
3050 - Parkville
Recruitment postcode(s) [2] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
Hong Kong
State/province [1] 0 0
Hong Kong
Country [2] 0 0
Hong Kong
State/province [2] 0 0
Shatin, New Territories
Country [3] 0 0
Korea, Republic of
State/province [3] 0 0
Gangwon-Do
Country [4] 0 0
Korea, Republic of
State/province [4] 0 0
Seoul
Country [5] 0 0
New Zealand
State/province [5] 0 0
Auckland
Country [6] 0 0
Singapore
State/province [6] 0 0
Singapore
Country [7] 0 0
Taiwan
State/province [7] 0 0
Kaohsiung City
Country [8] 0 0
Taiwan
State/province [8] 0 0
Kaohsiung
Country [9] 0 0
Taiwan
State/province [9] 0 0
Taipei City
Country [10] 0 0
Taiwan
State/province [10] 0 0
Taoyuan City
Country [11] 0 0
Thailand
State/province [11] 0 0
Bangkok
Country [12] 0 0
Thailand
State/province [12] 0 0
Chiang Mai

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This randomized study will be conducted in two parts to evaluate the safety, tolerability,
pharmacodynamics, and pharmacokinetics of subcutaneous administration of RO7062931. Part 1
will include only healthy participants and Part 2 will include only participants with chronic
hepatitis B (CHB). Part 1 is an adaptive, single-ascending dose study with an adaptive
dose-escalating schedule to determine the best dose to be evaluated in participants with CHB.
Part 2 is an adaptive, parallel multiple-dose study comprised of three sub-parts which will
be used to further refine the dose and dosing regimen, and to evaluate the safety and
efficacy of RO7062931 when administered with standard-of-care (SoC) therapy.
Trial website
https://clinicaltrials.gov/show/NCT03038113
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications